Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Authors

• Marcia S Brose
• Bhumsuk Keam
• Jolanta Krajewska
• Ana O Hoff
• Fernanda Vaisman
• Chia-Chi Lin
• Erika Hitre
• Daniel W Bowles
• Bruce Robinson
• Steven I Sherman
• Nuttapong Ngamphaiboon
• Xiang Guo
• Andrew Simmons
• Denise Williamson
• Svetlana Andrianova
• Nicholas Berry
• Jaume Capdevila

Publication/Presentation Date

1-1-2026

Abstract

BACKGROUND: Cabozantinib is approved for previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) based on improved progression-free survival (PFS) versus placebo in the COSMIC-311 study. The

METHODS: In this exploratory analysis, outcomes by

RESULTS: BRAF status was available for 106 of 258 patients enrolled in COSMIC-311; of these, 74 had

CONCLUSIONS: In this subgroup analysis of COSMIC-311, cabozantinib improved PFS and ORR versus placebo irrespective of

Volume

16

First Page

1748566

Last Page

1748566

ISSN

2234-943X

Published In/Presented At

Brose, M. S., Keam, B., Krajewska, J., Hoff, A. O., Vaisman, F., Lin, C. C., Hitre, E., Bowles, D. W., Robinson, B., Sherman, S. I., Ngamphaiboon, N., Guo, X., Simmons, A., Williamson, D., Andrianova, S., Berry, N., & Capdevila, J. (2026). Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. Frontiers in oncology, 16, 1748566. https://doi.org/10.3389/fonc.2026.1748566

Disciplines

Medicine and Health Sciences

PubMedID

41858341

Department(s)

Hematology-Medical Oncology Division

Document Type

Article